Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 14/20 | 0.73 |
| ▸ | LPL | P06858 | 13/20 | 0.73 |
| ▸ | F11 | P03951 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14022428 | 0.95 | LIPG (0.71) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL15025955 | 0.91 | LIPG (0.86) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL133316 | 0.90 | LIPG (0.87) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL22745551 | 0.85 | LPL (1.00) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL31329315 | 0.85 | LPL (0.71) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL10006068 | 0.84 | LIPG (0.81) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL18727878 | 0.83 | LPL (1.00) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL22666351 | 0.83 | LPL (0.97) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL14227371 | 0.83 | LPL (1.00) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL1353091 | 0.83 | LPL (1.00) | LIPGLPLF11F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666871-B2 | 3-Methyl-6-(4-{5-methyl-4-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-oxazol-2-yl}-phenyl)-pyridazine; for treatment of obesity, cognitive deficiencies, narcolepsy | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | ELI LILLY AND COMPANY | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | HCRTR1, HRH3, HCRTR2 | LIPG 4316/4885LPL 3172/4885F11 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.